| abstract |
Provided is a recombinantly-expressed mutant antibody with enhanced affinity for TL1A and a higher titer than the parent antibody from which they are derived. This antibody inhibits the interaction between TL1A and cell death receptor 3 (DR3). Using the antibody or composition thereof, asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, gastrointestinal disease related to cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, One or more of irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis may be treated. |